Lupus & antiphospholipid syndrome
A high level of sTREM-1 predicts occurrence of thrombosis, obstetrical event or death in a prospective cohort of patients with antiphospholipid antibodies and/or systemic lupus. Results of the APLART study
Authors' conclusion
High levels of sTREM-1 at inclusion predicted the occurrence of a thrombotic and obstetric event or death in patients with aPL and/or SLE.
Study context
- Population
- Patients with antiphospholipid syndrome (APS), isolated aPL or systemic lupus erythematosus (SLE) (APLART study)followed 46 months
- Participants
- 108 patients
- Exposure
- Elevated vs lower serum sTREM-1 levels at inclusion
- Outcome
- Composite of:
- Thrombosis
- Death
- Obstetrical morbidity (first event of interest)
Methodological detailsmultivariable Cox model
- Multivariable Cox model
Main finding
As reported in the abstract
Composite outcome (thrombosis, death, obstetrical morbidity), predicted by elevated serum sTREM-1
Elevated serum sTREM-1 levels: independent predictor of the composite outcome, HR (95% CI 2.44-23.31), p < .001
7.54
Thromboses during follow-up, n (14%)
15
Deaths during follow-up, n (5%)
5
Women with obstetrical morbidities, n (3%)
3
Observational data: associations, not effects.
Further findings
- sTREM-1 levels greater in patients with APS than patients with isolated aPL (p < .01)
Original publication
A high level of sTREM-1 predicts occurrence of thrombosis, obstetrical event or death in a prospective cohort of patients with antiphospholipid antibodies and/or systemic lupus. Results of the APLART study. Lupus. Published 13 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →